Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor- selective tyrosine kinase inhibitor

Clinical Cancer Research

Volumn 6, Issue 5, 2000, Pages 2053-2063

  Ciardiello, Fortunato ^a   Caputo, Rosa ^a   Bianco, Roberto ^a   Damiano, Vincenzo ^a   Pomatico, Grazia ^a   De Placido, Sabino ^a   Bianco, A Raffaele ^a   Tortora, Giampaolo ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; CYTOTOXIC AGENT; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ETOPOSIDE; GEFITINIB; OXALIPLATIN; PACLITAXEL; PROTEIN TYROSINE KINASE INHIBITOR; QUINAZOLINE DERIVATIVE; RALTITREXED; TOPOTECAN; TRANSFORMING GROWTH FACTOR ALPHA; TRANSFORMING GROWTH FACTOR ALPHA RECEPTOR;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; CYTOSTASIS; DRUG ACTIVITY; DRUG POTENTIATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR GROWTH;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARBOPLATIN; CELL DIVISION; CISPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; FEMALE; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; ORGANOPLATINUM COMPOUNDS; PACLITAXEL; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SURVIVAL RATE; TAXOIDS; THIOPHENES; TOPOTECAN; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 0034068319     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. Salomon, D. S., Brandt, R., Ciardiello, F., and Normanno, N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit. Rev. Oncol. Hematol., 19: 183-232, 1995.
2. Pawson, T. Protein modules and signaling networks. Nature (Lond.), 373: 573-579, 1994.
3. Fox, S. B., Smith, K., Hollyer, J., Greenall, M., Hastrich, D., and Harris, A. L. The epidermal growth factor receptor as a prognostic marker: results of 370 patients and review of 3009 patients. Breast Cancer Res. Treat., 29: 41-49, 1994.
4. Wosikowski, K., Schuurhuis, D., Kops, G. J. P. L., Saceda, M., and Bates, S. E. Altered gene expression in drug-resistant human breast cancer cells. Clin. Cancer Res., 3: 2405-2414, 1997.
5. Fan, Z., and Mendelsohn, J. Therapeutic application of anti-growth factor receptor antibodies. Curr. Opin. Oncol., 10: 67-73, 1998.
6. Strawn, L. M., and Shawver, L. K. Tyrosine kinases in disease: overview of kinase inhibitors as therapeutic agents and current drugs in clinical trials. Exp. Opin. Investig. Drugs, 7: 553-573, 1998.
7. Baselga, J., and Mendelsohn, J. Type I receptor tyrosine kinases as targets for therapy in breast cancer. J. Mammary Gland Biol. Neopl., 2: 165-174, 1997.
8. Mendelsohn, J. Epidermal growth factor receptor inhibition by a monoclonal antibody as anticancer therapy. Clin. Cancer Res., 3: 2703-2707, 1997.
9. Masui, H., Kamrath, H., Apell, G., Houston, L. L., and Mendelsohn, J. Cytotoxicity against human tumor cells mediated by the conjugate of anti-epidermal growth factor receptor monoclonal antibody to recombinant ricin A chain. Cancer Res., 49: 3482-3488, 1989.
10. Arteaga, C. L., Hurd, S. D., Dugger, T. C., Winnier, A. R., and Robertson, J. B. Epidermal growth factor receptors in human breast carcinoma cells: a potential selective target for transforming growth factor α-Pseudomonas exotoxin 40 fusion protein. Cancer Res., 54: 4703-4709, 1994.
11. Kirk, J., Carmichael, J., Stratford, I. J., and Harris, A. L. Selective toxicity of TGF-α-PE40 to EGFR-positive cell lines: selective protection of low EGFR-expressing cell lines by EGF. Br. J. Cancer, 69: 988-994, 1994.
12. Schmidt, M., and Wels, W. Targeted inhibition of tumor cell growth by a bispecific single-chain toxin containing an antibody domain and TGFα. Br. J. Cancer, 74: 853-862, 1996.
13. Aboud-Pirak, E., Hurwitz, E., Pirak, M. E., Bellot, F., Schlessinger, J., and Sela, M. Efficacy of antibodies to epidermal growth factor receptor against KB carcinoma in vitro and in nude mice. J. Natl. Cancer Inst., 80: 1605-1611, 1988.
14. Modjtahedi, H., Eccles, S., Box, G., Styles, J., and Dean, C. Immunotherapy of human tumour xenografts overexpressing the EGF receptor with rat antibodies that block growth factor-receptor interaction. Br. J. Cancer, 67: 254-261, 1993.
15. Fry, D. W. Inhibition of the epidermal growth factor receptor family of tyrosine kinases as an approach to cancer chemotherapy: progression from reversible to irreversible inhibitors. Pharmacol. Ther., 82: 207-218, 1999.
16. Goldstein, N. I., Prewett, M., Zuklys, K., Rockwell, P., and Mendelsohn, J. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin. Cancer Res., 1: 1311-1318, 1995.
17. Anderson, V., Cooper, M., O'Chei, E., Gilly, J., Falcey, J., and Waksal, H. W. Dose dependent pharmacokinetics of a chimerized monoclonal antibody (C225) against EGFR. Proc. Am. Assoc. Cancer Res., 39: 3561, 1998.
18. Mendelsohn, J., Shin, D. M., Donato, N., Khuri, F., Radinsky, R., Glisson, B. S., Shin, H. I., Metz, E., Pfister, D., Perez-Soler, R., Lawhorn, K., Matsumoto, T., Gunnett, K., Falcey, J., Waksal, H., and Hong, W. K. A Phase I study of chimerized anti-epidermal growth factor receptor (EGFr) monoclonal antibody, C225, in combination with cisplatin (CDDP) in patients (PTS) with recurrent head and neck squamous cell carcinoma (SCC). Proc. Am. Soc. Clin. Oncol., 18: 1502, 1999.
19. Gunnett, K., Motzer, R., Amato, R., Todd, M., Poo, W-J., Cohen, R., Baselga, J., Cooper, M., Robert, F., Falcey, J., and Waksal, H. Phase II study of anti-epidermal growth factor receptor (EGFr) antibody C225 alone in patients (pts) with metastatic renal cell carcinoma (RCC). Proc. Am. Soc. Clin. Oncol., 18: 1309, 1999.
20. Fry, D. W., Kraker, A. J., McMichael, A., Ambroso, L. A., Nelson, J. M., Leopold, W. R., Connors, R. W., and Bridges, A. J. A specific inhibitor of the epidermal growth factor receptor tyrosine kinase. Science (Washington DC), 265: 1093-1095, 1994.
21. Buchdunger, E., Mett, H.. Trinks, U., Regenass, U., Muller, M., Meyer, T., Beilstein, P., Wirz, B., Schneider, P., Traxler, P., and Lydon, N. 4,5-Bis(4-fluoroanilino)phthalimide: a selective inhibitor of the epidermal growth factor receptor signal transduction pathway with potent in vivo antitumor activity. Clin. Cancer Res., 1: 813-821, 1995.
22. Moyer, J. D., Barbacci, E. G., Iwata, K. K., Arnold, L., Boman, B., Cunningham, A, DiOrio, C., Doty, J., Morin, M., Moyer, M. P., Neveu, M., Pollack, V. A., Pustilnik, L. R., Reynolds, M. M., Sloan, D., Theleman, A., and Miller, P. Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res., 57: 4838-4848, 1997.
23. Bos, M., Mendelsohn, J., Kim, Y-M., Albanell, J., Fry, D. W., and Baselga, J. PD153035, a tyrosine kinase inhibitor, prevents epidermal growth factor receptor activation and inhibits growth of cancer cells in a receptor number-dependent manner. Clin. Cancer Res., 3: 2099-2106, 1997.
24. Baguley, B. C., Marshall, E. S., Holdaway, K. M., Rewcastle, G. W., and Denny, W. A. Inhibition of growth of primary human tumour cell cultures by a 4-anilinoquinazoline inhibitor of the epidermal growth factor receptor family of tyrosine kinases. Eur. J. Cancer, 34: 1086-1090, 1998.
25. Simpson, B. J., Bartlett, J. M., Macleod, K. G., Rabiasz, G., Miller, E. P., Rae, A. L., Gordge, P., Leake, R. E., Miller, W. R., Smyth, J., and Langdon, S. P. Inhibition of transforming growth factor a (TGF-α)-mediated growth effects in ovarian cancer cell lines by a tyrosine kinase inhibitor ZM 252868. Br. J. Cancer, 79: 1098-1103, 1999.
26. Wakeling, A. E., Barker, A. J., Davies, D. H., Brown, D. S., Green, L. R., Cartlidge, S. A., and Woodburn, J. R. Specific inhibition of epidermal growth factor receptor tyrosine kinase by 4-anilinoquinazolines. Breast Cancer Res. Treat., 38: 67-73, 1996.
27. Woodburn, J. R., Barker, A. J., Gibson, K. H., Ashton, S. E., Wakeling, A. E., Curry, B. J., Scarlett, L., and Henthorn, L. R. ZD1839, an epidermal growth factor receptor tyrosine kinase inhibitor selected for clinical development. Proc. Am. Assoc. Cancer Res., 38: 4251, 1997.
28. Sun, Y., Fry, D. W., Vincent, P., Nelson, J. M., Elliott, W., and Leopold, W. R. Growth inhibition of nasopharyngeal carcinoma cells by EGF receptor tyrosine kinase inhibitors. Anticancer Res., 19: 919-924, 1999.
29. Dinney, C. P. N., Parker. C., Dong, Z., Fan, D., Eve, B. Y., Bucana, C., and Radinsky. R. Therapy of human transitional cell carcinoma of the bladder by oral administration of the epidermal growth factor receptor protein tyrosine kinase inhibitor 4,5-dianilinophtalimide. Clin. Cancer Res., 3: 161-168, 1997.
30. Hammond, L., Ranson, M., Ferry, D., Kris, M., Kelly, H., Ochs, J., Averbuch, S., and Rowinsky, E. ZD1839, an oral epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor: first Phase I, pharmacokinetic (PK) results in patients. Proc. Am. Soc. Clin. Oncol., 18: 1500, 1999.
31. Fan, Z., Baselga, J., Masui, H., and Mendelsohn, J. Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts. Cancer Res., 53: 4637-4642, 1992.
32. Baselga, J., Norton, L., Masui, H., Pandiella, A., Coplan, K., Miller, W. H., and Mendelsohn, J. Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies. J. Natl. Cancer Inst., 85: 1327-1333, 1993.
33. Ciardiello, F., Bianco, R., Damiano, V., De Lorenzo, S., Pepe, S., De Placido, S., Fan, Z., Mendelsohn, J., Bianco, A. R., and Tortora, G. Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225. Clin. Cancer Res., 5: 909-916, 1999.
34. Tortora, G., Caputo, R., Pomatico, G., Pepe, S., Bianco, A. R., Agrawal, S., Mendelsohn. J., and Ciardiello, F. Cooperative inhibitory effect of novel mixed backbone oligonucleotide targeting protein kinase A in combination with docetaxel and anti-EGF-receptor antibody on human breast cancer cell growth. Clin. Cancer Res., 5: 875-881, 1999.
35. Hoffmann, T., Hafner, D., Ballo, H., Haas, I., and Bier, H. Antitumor activity of anti-epidermal growth factor receptor monoclonal antibodies and cisplatin in ten human head and neck squamous cell carcinoma lines. Anticancer Res., 17: 4419-4425, 1997.
36. Hancock, M. C., Langton, B. C., Chan, T., Toy, P., Monhanan, J. J., Mischak, R. P., and Shawver, L. K. A monoclonal antibody against the c-erbB-2 protein enhances the cytotoxicity of cis-diamminedichloro-platinum against human breast and ovarian tumor cell lines. Cancer Res., 51: 4574-4580, 1991.
37. Arteaga, C. L., Winnier, A. R., Poirer, M. C., Lopez-Larraza, D. M., Shawer, L. K, Hurd, S. D., and Stewart, S. J. p185c-erbB-2 signaling enhances cisplatin-induced cytotoxicity in human breast carcinoma cells: association between an oncogenic receptor tyrosine kinase and drug-induced DNA repair. Cancer Res., 54: 3758-3765, 1994.
38. Pietras, R. J., Fendly, B. M., Chazin, V. R., Pegram, M. D., Howell, S. B., and Slamon, D. J. Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. Oncogene, 9: 1829-1838, 1994.
39. Pietras, R. J., Pegram, M. D., Finn, R. S., Maneval, D. A., and Slamon, D. J. Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs. Oncogene, 17: 2235-2249, 1998.
40. Baselga, J., Norton, L., Albanell, J., Kim, Y-M., and Mendelsohn, J. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res., 58: 2825-2831, 1998.
41. HER2/new monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J. Clin. Oncol., 16: 2659-2671, 1998.
42. Slamon, D. J., Leyland-Jones, B., Shak, S., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Volter, J., Baselga, J., and Norton, L. Addition of Herceptin (humanized anti-HER2 antibody) to first line chemotherapy for HER2 overexpressing metastatic breast cancer markedly increases anticancer activity: a randomized multinational controlled Phase III trial. Proc. Am. Soc. Clin. Oncol., 17: 377, 1998.
43. Ciardiello, F., McGeady, M. L., Kim, N., Basolo, F., Hynes, N. E., Langton, B., Yokozaki, H., Saeki, T., Elliott, J., Masui, H., Mendelsohn, J., Soule, H., Russo, J., and Salomon, D. S. Transforming growth factor-α expression is enhanced in human mammary epithelial cells transformed by an activated c-Ha-ras protooncogene but not by the c-neu protooncogene, and overexpression of the transforming growth factor-α complementary DNA leads to transformation. Cell Growth Differ., 1: 407-420, 1990.
44. Tortora, G., Damiano, V., Bianco, C., Baldassarre, G., Bianco, A. R., Lanfrancone, L., Pelicci, P. G., and Ciardiello, F. The RIα subunit of protein kinase A (PKA) binds to Grb2 and allows PKA interaction with the activated EGF-receptor. Oncogene, 14: 923-928, 1997.
45. De Luca, A., Casamassimi, A., Selvam, M. P., Losito, S., Ciardiello, F., Agrawal, S., Salomon, D. S., and Normanno, N. EGF-related peptides are involved in the proliferation and survival of MDA-MB-468 human breast carcinoma cells. Int. J. Cancer, 80: 589-594, 1999.
46. Fleiss, J. L. Statistical Methods for Rates and Proportions, Ed. 2. New York: John Wiley & Sons, Inc., 1981.
47. Mantel, N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother. Rep., 50: 163-170, 1966.
48. Wu, X., Fan, Z., Masui, H., Rosen, N., and Mendelsohn, J. Apoptosis induced by an anti-epidermal growth factor receptor monoclonal antibody in a human colorectal carcinoma cell line and its delay by insulin. J. Clin. Investig., 95: 1897-1905, 1995.
49. Ciardiello, F., Damiano, V., Bianco, R., Bianco, C., Fontanini, G., De Laurentiis, M., De Placido, S., Mendelsohn, J., Bianco, A. R., and Tortora, G. Antitumor activity of combined blockade of epidermal growth factor receptor and protein kinase A. J. Natl. Cancer Inst., 88: 1770-1776, 1996.
50. Tortora, G., Caputo, R., Damiano, V., Bianco, R., Pepe, S., Bianco, A. R., Jiang, Z., Agrawal, S., and Ciardiello, F. Synergistic inhibition of human cancer cell growth by cytotoxic drugs and mixed backbone antisense oligonucleotide targeting protein kinase A. Proc. Natl. Acad. Sci. USA, 94: 12586-12591, 1997.
51. Mendelsohn, J., and Fan, Z. Epidermal growth factor receptor family and chemosensitization. J. Natl. Cancer Inst., 89: 341-343, 1997.
52. Baselga, J., LoRusso, P., Herbst, R., Rischin, D., Ranson, M., Maddox, A-M., Feyereislova, A., and Averbuch, S. A pharmacokinetic/pharmacodynamic trial of ZD1839 ("Iressa"), a novel oral epidermal growth factor receptor tyrosine kinase (EGFR-TK) inhibitor, in patients with five selected tumor types (a Phase I/II trial of continuous once-daily treatment). AACR-NCI-EORTC Meeting on Molecular Targets and Cancer Therapeutics, abstract 29. Clin. Cancer Res., 5: 3735s, 1999.
53. Kris, M., Ranson, M., Ferry, D., Hammond, L., Averbuch, S., Ochs, J., and Rowinsky, E. Phase I study of oral ZD1839 ("Iressa"), a novel inhibitor of epidermal growth factor receptor tyrosine kinase (EGFR-TK): evidence of good tolerability and activity. AACR-NCI-EORTC Meeting on Molecular Targets and Cancer Therapeutics, abstract 99. Clin. Cancer Res., 5: 3749s-3750s, 1999.